https://en.bioecon.ru/niches/bio-pharma/Recent content in Bio-Pharma on BioeconHugoen-USSat, 25 Jul 2026 22:12:11 +0700https://en.bioecon.ru/technology/single-use-bag-bioreactors-50l-2000l/Fri, 24 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/single-use-bag-bioreactors-50l-2000l/Gamma-irradiated single-use bag bioreactors in the 50-2000 L stirred-tank class — Sartorius Biostat STR, Cytiva Xcellerex XDR, Thermo Fisher HyPerforma, Merck Mobius — that replaced stainless steel for clinical and commercial mAb, vaccine and cell-and-gene-therapy manufacturing, cutting facility build-out from years to weeks and underpinning the CDMO economy.https://en.bioecon.ru/technology/biosafety-lab-biosecurity/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/biosafety-lab-biosecurity/Physical-containment infrastructure — biological safety cabinets, HEPA filtration, autoclave sterilization and BSL-1 to BSL-4 containment — that protects personnel, product and environment in every biotechnology laboratory, governed by NSF/ANSI 49 and EN 12469.https://en.bioecon.ru/technology/dna-synthesis-gene-foundry/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/dna-synthesis-gene-foundry/The commercial gene-synthesis service and biofoundry layer of synthetic biology — turning digital DNA designs into delivered genes, clones and strain builds through phosphoramidite and emerging enzymatic synthesis, governed by pathogen-sequence biosecurity screening.https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.https://en.bioecon.ru/technology/mini-bioreactors-doe-screening/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/mini-bioreactors-doe-screening/Automated mini- and micro-bioreactors (1-250 mL) running 24-48 cultures in parallel that map a bioprocess Design Space in days rather than months — the high-throughput on-ramp to cell-line, strain and upstream-process development, led by the German ambr, BioLector and DASbox platforms.https://en.bioecon.ru/technology/reference-materials-certified-reference-strains/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/reference-materials-certified-reference-strains/Authenticated microbial type strains and WHO biological reference materials — the calibrated living standards underpinning pharmaceutical QC, diagnostics, taxonomy and patent deposit, held by a global network of biological resource centers from the century-old ATCC to NIBSC.https://en.bioecon.ru/technology/hazardous-biomaterials-transport/Mon, 06 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/hazardous-biomaterials-transport/Regulated door-to-door transport of Category A and B infectious substances under IATA Packing Instructions 602/650, using triple packaging, biosafety couriers and chain-of-custody tracking.https://en.bioecon.ru/technology/microbiome-therapeutics-lbps/Wed, 01 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/microbiome-therapeutics-lbps/Live biotherapeutic products (LBPs) — standardized, GMP-manufactured microbial consortia approved as drugs for recurrent C. difficile, inflammatory bowel disease and immuno-oncology support.https://en.bioecon.ru/technology/antibiotics-new-gen-anti-amr/Mon, 01 Jan 0001 00:00:00 +0000https://en.bioecon.ru/technology/antibiotics-new-gen-anti-amr/Next-generation antimicrobial compounds and combinations designed to overcome multi-drug resistant (MDR) bacterial infections and address the global AMR crisis.https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/Mon, 01 Jan 0001 00:00:00 +0000https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/Targeted oncology therapies utilizing monoclonal antibodies to deliver highly potent cytotoxic payloads directly to cancer cells, minimizing systemic toxicity.https://en.bioecon.ru/technology/bacteriophage-therapy/Mon, 01 Jan 0001 00:00:00 +0000https://en.bioecon.ru/technology/bacteriophage-therapy/Utilizing naturally occurring or precision-engineered bacterial viruses to selectively target and eradicate specific pathogenic bacterial strains without harming the microbiome.https://en.bioecon.ru/technology/gene-therapy/Mon, 01 Jan 0001 00:00:00 +0000https://en.bioecon.ru/technology/gene-therapy/Precision delivery of functional genetic material via engineered vectors to treat inherited diseases and severe genetic disorders at their root cause.